Biomea Fusion, Inc.

NasdaqGS BMEA

Biomea Fusion, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -112.73 M

Biomea Fusion, Inc. Operating Cash Flow is USD -112.73 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -19.98% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Biomea Fusion, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -93.96 M, a -61.67% change year over year.
Biomea Fusion, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -58.12 M, a -160.90% change year over year.
Biomea Fusion, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -22.27 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqGS: BMEA

Biomea Fusion, Inc.

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road
Employees	107
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Clinical Trials Pharmaceuticals

Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends

Past 5 years